BioLife Solutions, Inc. (BLFS) P/E Ratio History
Insufficient DataValuation data unavailable. · Data 2002–2026
Loading P/E history...
P/E Ratio Analysis
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BLFS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BLFS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BLFS P/E vs Peers
Bioprocessing & Lab Consumables peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 6.5Lowest | 4.35 | +104%Best | |
| $4B | 21.2 | 2.48Best | -17% | |
| $258B | 36.4 | 17.23 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
BLFS Historical P/E Data (2002–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $28.24 | $1.02 | 27.6x | -85% |
| FY2021 Q3 | - | $42.32 | $0.09 | 486.4x | +161% |
| FY2021 Q2 | Jun 30 2021 | $44.51 | $0.05 | 901.0x | +383% |
| FY2020 Q4 | - | $39.89 | $0.25 | 157.7x | -16% |
| FY2020 Q3 | Sep 30 2020 | $28.94 | $0.34 | 84.1x | -55% |
| FY2020 Q2 | - | $16.35 | $0.73 | 22.4x | -88% |
| FY2020 Q1 | - | $9.50 | $1.45 | 6.5x | -96% |
| FY2018 Q4 | Dec 31 2018 | $12.03 | $0.12 | 97.2x | -48% |
| FY2018 Q3 | Sep 30 2018 | $17.50 | $0.04 | 452.2x | +142% |
| FY2003 Q1 | Mar 31 2003 | $1.68 | $1.31 | 1.3x | -99% |
| FY2002 Q4 | - | $1.68 | $1.26 | 1.3x | -99% |
| FY2002 Q3 | Sep 30 2002 | $1.96 | $0.65 | 3.0x | -98% |
Average P/E for displayed period: 186.7x
BLFS Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
24+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BLFS — Frequently Asked Questions
Quick answers to the most common questions about buying BLFS stock.
What is BLFS's P/E ratio?
BioLife Solutions, Inc. (BLFS) trailing twelve-month P/E ratio is N/A, based on TTM diluted EPS of N/A. The 5-year average P/E is 186.7x and the historical range spans 1.3x to 901.0x.
Is BLFS stock overvalued or undervalued?
BLFS current P/E: N/A. 5-year average P/E: 186.7x. Percentile: N/A.
Is BLFS stock expensive?
BLFS is fairly valued relative to its own history. The current P/E of N/A is near the 5-year average of 186.7x (N/A percentile of historical range).
What is BLFS's historical P/E range?
Over the past 5 years, BLFS's P/E ratio has ranged from 1.3x to 901.0x, with a median of 84.1x and an average of 186.7x. The current P/E of N/A places the stock at the N/A percentile of this range. Full historical data spans 2002–2026.
How does BLFS's P/E compare to the S&P 500?
BLFS current P/E: N/A. S&P 500 median P/E: 21.8x.
How does BLFS's valuation compare to Healthcare peers?
BioLife Solutions, Inc. P/E of N/A can be benchmarked against Healthcare peers in the comparison table on this page.
What is BLFS's PEG ratio?
BLFS PEG ratio is N/A. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BLFS's earnings yield?
BLFS earnings yield is N/A, the inverse of its N/A P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.